However, a recent study by Kaufman et al. using an LKB1 loss-associated gene expression signature suggested that human lung cancer differs substantially from the expression profile of the krasG12D/lkb1 floxed GEM model [33], therefore raising the concern that the sensitivity to MEK inhibition observed in GEM models may not be extrapolated to human lung cancer with LKB1 mutation. The gene discussed is STK11; the disease is lung cancer.